Company intelligence / Profile preview

Axxonis Pharma AG

Berlin, Berlin, Germanypwc.com ↗

Ownership: Private
Development stage: Other

Overview

Axxonis has completed a successful Phase III clinical program for the lisuride patch in the treatment of RLS. They have also reported positive results from a Phase III clinical trial of transdermal lisuride in patients with advanced Parkinson's Disease. In a longterm controlled double-blind study (CALIPSO), lisuride sc infusion therapy proved highly effective in reducing severe motor complications in patients with Parkinson's Disease.

Therapeutic areas: CardiovascularNeurology
Modalities: Small moleculesTransdermal patchesParenteral applications
Industry: Biotech

Beyond the preview

Go deeper on Axxonis Pharma AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axxonis Pharma AG.

Explore the full profile